Cidara Therapeutics, Inc. (CDTX)

USD 20.53

(-10.0%)

Market Cap (In USD)

144.66 Million

Revenue (In USD)

63.9 Million

Net Income (In USD)

-22.93 Million

Avg. Volume

23.51 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.0-24.99
PE
-
EPS
-
Beta Value
0.994
ISIN
US1717571079
CUSIP
171757107
CIK
1610618
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jeffrey L. Stein Ph.D.
Employee Count
-
Website
https://www.cidara.com
Ipo Date
2015-04-15
Details
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.